DAFTAR PUSTAKA

1. IARC (International Agency for Research on Cancer) tahun 2012.

2. Laporan Nasional 2010. Badan Penelitian dan Pengembangan Kesehatan, Departemen

Kesehatan RI.

3. Sirait, M. A., Oemiati, R., dan Indrawati, L. (2009). Hubungan kontrasepsi pil dengan

tumor/kanker payudara. Artikel penelitian Majalah Kedokteran Indonesia. Pusat Penelitian

dan Pengembangan Biomedis Farmasi, Badan Penelitian dan Pengembangan Departemen

Kesehatan Republik Indonesia. Vol. 59. No. 8.

4. Kementrian Kesehatan (Kemenkes) RI. 2012.

5. Sjamsuhidajat, R. & Jong, Wim de, 2005, Buku Ajar Ilmu Bedah, Jakarta: EGC.

6. Sutandyo, Noorwati. 2007. Terapi Hormonal Pada Kanker dalam Sudoyo, Aru W.

Setiyohadi,Bambang. Alwi, Idrus. Simadibrata K, Marcellus. Setiati, Siti. Buku Ajar Ilmu

Penyakit Dalam Jilid I Edisi IV. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam

FKUI.

7. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival

in adult malignancies. Clin Oncol (R Coll Radiol). 2004 Dec; 16(8): 549-60.

8. Minckwitz GV, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B,

Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M,. Konecny GE, Denkert C,

Nekljudova V, Mehta K, Loibl S. Definition and Impact of Pathologic Complete Response on

Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes.

American Society of Clinical Oncology. 2012 May; vol. 30 no. 15.

9. Swisher SG, Pataer A, Roth JA, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein

kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther.

2009; 8: 245–252.

10. Manuaba, IBTW. Panduan Penatalaksanaan Kanker Payudara Peraboi 2010. Panduan

Penatalaksanaan Kanker Solid: Sagung Seto 2010. p. 17-50.

11. Carlson, R.W., 2008. Continuous Intravenous Infusion Chemotherapy. In: Michael Clinton

Perry., ed. The Chemotherapy Source Book Fourth Edition. Philadelphia: Lippincott

Williams & Wilkins, 79-85.

12. Baretta G. Cancer treatment Medical Guide. 10th ed. Milan: Farmitalia Carlo Erba; 1991. P.

174-6.

13. Bapat SA. Human Ovarian Cancer Stem Cells. Reproduction, July 2010; 140(1): 33-41.

14. Bhattacharyya S, Khanduja KL. New Hope in The Horizon: Cancer stem cells. Acta Biochim

Biophys Sin. 2010; 42(4): 237-42.

15. Jordan CT, Guzman ML, Noble M. Cancer stem cells. The New England Journal of

Medicine. 2006; 355:1253-61.

16. Cariati M, Purushotham AD. Stem cells and breast cancer. Histopathology. 2008, 52, 99–107.

17. Phuc PV, Nhan PLC, Nhung TH, Tam NT, Nguyen, Hoang NM, Tue VG, Thuy DT, Ngoc

PK. Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24− breast cancer

cells. Dove Press Journal: Onco Targets and Therapy. 2011; 4: 71-78.

18. Sariego J (2010). "Breast cancer in the young patient". The American surgeon 76 (12): 1397–

1401.

19. American Cancer Society. Breast Cancer 2011. Atlanta, Ga: American Cancer Society; 2011.

20. Kakarala M, Wicha MS (2008) Implications of the cancer stem-cell hypothesis for breast

cancer prevention and therapy. J Clin Oncol 26 (17):2813–2820. doi:26/17/2813 [pii]

10.1200/JCO.2008.16.3931.

21. Kalirai H, Clarke RB (2006) Human breast epithelial stem cells and their regulation. J Pathol

208 (1): 7–16. Doi: 10.1002/path.1881.

22. Price, Sylvia Anderson. (2006). Patofisiologi: Konsep Klinis Proses-Proses Penyakit. Jakrata:

EGC.

23. Lindley and Michaud dalam Dipiro J., Wells B., Schwinghammer T., Dipiro C., 2005,

Pharmacotherapy: A Patophysiological Approach, 2354-2361, 8th Ed, McGraw Hill

Company, New York.

24. Greenwald, P., 2002, Cancer Chemopevention, BMJ, 324:714-718.

25. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev

Clin Oncol. 2010 Dec;7(12): 702-7.

26. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA

damage. J Cell Sci. 2001 Oct; 114(Pt 20): 3591-8.

27. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of

genome protection. Nat Rev Cancer. 2011 Dec 23; 12(1): 68-78.

28. Ahmad (2008), Aspek Dasar Sel Punca Embrionik (Embryonic Stem Cell) dan Potensi

Pengembangannya, Dipresentasikan pada diskusi panel “Realitas Baru dan Prospek

Perkembangan seputar Terapi Sel Punca (Stem Cell), R. Rapat PB IDI, Jakarta, Sabtu 24 Mei

2008.

29. National Institutes of Health (2009), U.S. Department of Health and Human Services.

30. Liang YJ, Ding Y, B Steven. Leveryd, Lobatona M, Handa, and Hakomori S. Differential

expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-

stem cells. Proceedings of the national Academy of Sciences of USA. 2013; vol. 110 no. 13.

31. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23: 7274-

82.

32. Stocum DL. An Overview of Regenerative Biology and Medicine. Dalam buku: Regenerative

Biology and Medicine. Elsevier. 2006: 1-20.

33. Bunting KD. ABC Transporters as Phenotypic Markers and Functional Regulators of Stem

Cells. Stem Cells. 2002; 20: 11-20.

34. Hurt EM, Farrar WL. Purification and Characterization of Cancer stem cells. Dalam: Cancer

stem cells. Editor: William L. Farrar. Cambridge University Press. 2010: 1-14.

35. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of

CD44+ ⁄ CD24- ⁄ low cells in breast cancer may not be associated with clinical outcome but

may favor distant metastasis. Clin. Cancer Res. 2005; 11; 1154–1159.

36. Jeanne M. V. Louderbough, Jessie A. Brown, Ray B. Nagle, Joyce A. Schroeder. CD44

Promotes Epithelial Mammary Gland Development and Exhibits Altered Localization during

Cancer Progression. Genes Cancer. 2011 August; 2(8): 771–781. doi:

10.1177/1947601911428223.

37. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H,

Sleeman JP (2005) Cd24 expression causes the acquisition of multiple cellular properties

associated with tumor growth and metastasis. Cancer Res 65 (23):10783–10793. doi:

65/23/10783 [pii] 10.1158/0008-5472.CAN-05-0619.

38. Lim SC (2005) Cd24 and human carcinoma: Tumor biological aspects. Biomed

Pharmacother 59 Suppl 2:S351–354. doi:S0753-3322(05)80076-9 [pii].

39. Modul In House Training Kemoterapi RS Kanker Dharmais tahun 2012.

40. Hunt KK, Newman LA, Copeland EM, Bland KI. The breast. In: Schwartz’s principles of

surgery. 9th ed. USA: Mc Graw-Hill; 2010. p. 423-74.

41. Chu E, De Vita VC. Principles of Medical Oncology. In: De Vita VC, Hellman S, Rosenberg

SA. eds. Cancer, principles & practice of oncology. 7th ed. Philadelphia (USA): Lippincott

William & Wilkins; 2003. p 95-306.

42. Tjindarbumi D. Penanganan kanker payudara masa kini dengan berbagai macam issue di

indonesia. Dalam: Indonesian issues on breast cancer 1; 28-29 Februari 2004; Hptel Sheraton

di Surabaya. PERABOI Surabaya: 2004.

43. Smart, Aqila, 2010, Kanker Organ Reproduksi, Darul Hikmah, Jogjakarta.

44. Gale, Danielle & Charette, Jane. (2000). Rencana asuhan keperawatan onkologi. Jakarta :

EGC

45. Childs, A.C., Phaneuf, S.L., Dirks, A.J., Phillips, T., and Leeuwenburgh, 2002, Doxorubicin

Treatment In Vivo Causes Cytochrome c Release and Cardiomyocyte Apoptosis, as well as

Increased Mitochondrial Efficiency, Superoxide Dismutase Activity, and Bcl-2:Bax Ratio,

Cancer Res, 62: 4592-4598.

46. Minotti, G., Menna, P., Salvatorelli, E., Cairo,G., and Gianni, L. 2004. Anthracyclins:

Molecular Advances and Pharmacologic Developments in Antitumor Activity and

Cardiotoxicity. Pharmacol Rev., 56:185-228.

47. Bruton, L., Lazo, J. S., and Parker, K. L., 2005, Goodman & Gilman’s The Pharmacological

Basis of Therapeutics, 11th Edition, Mc Graw Hill, Lange.

48. Gewirtz, D.A., 1999, A critical evaluation of the mechanisms of action proposed for the

antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin, Biochem.

Pharmacol., 57:727-741.

49. Serrano, J., Palmeira, C.M., Kuehl, D.W., and Wallace, K.B., 1999, Cardioselective and

Cumulative Oxidation of Mitochondrial DNA Following Subchronic Doxorubicin

Administration, Biochem. Biophys. Acta, 1411 : 201-205.

50. Doroshow JH. Anthracyclines and Biotherapy: Principles and Practice. 4th edition.

Philadelphia, Lippincott William & Wilkins. 2006: 415-27.

51. ATCC-The Essentials of Live Science Research, 2012. www.atcc.org. Diakses tanggal 16

Juni 2013.

52. Feridoun Karimi-Busheri, Aghdass Rasouli-Nia, John R Mackey, Michael Weinfeld.

Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Research.

June 2010, 12:R31. Doi: 10.1186/bcr2583